<DOC>
	<DOCNO>NCT00215839</DOCNO>
	<brief_summary>Objectives : Primary To evaluate safety , tolerability , efficacy Peginterferon a-2a plus Ribavirin treatment chronic hepatitis C ( CHC ) infection person co-infected human immunodeficiency virus ( HIV ) fail achieve sustain virologic response follow previous interferon therapy . Secondary - To evaluate virological response Peginterferon a-2a plus Ribavirin week 12 24 compare baseline value . - To evaluate sustained virological response Peginterferon a-2a plus Ribavirin post-treatment week 4 , 12 , 24 compare baseline . - To evaluate histological effect long-term Peginterferon a-2a therapy comparison liver biopsy result follow 96 week Peginterferon a-2a therapy baseline value . - To evaluate safety tolerability long-term Peginterferon a-2a therapy patient previously fail achieve sustain virologic response follow interferon therapy . - To investigate effect long-term Peginterferon a-2a therapy clinical outcome HIV disease . Study Design : All qualify patient enter treatment phase dose follow : Peginterferon a-2a 180mg subcutaneous route weekly plus Ribavirin : - 800 mg ( 400 mg bid ) body weight &lt; 65 kg - 1000 mg ( 400 mg a.m. 600 mg p.m. ) body weight &gt; 65 kg &lt; 85 kg - 1200 mg ( 600 mg bid ) body weight &gt; 85 kg Patients undetectable level HCV-RNA Treatment Week 24 continue previously assign Peginterferon a-2a plus Ribavirin combo-therapy additional 24 week . Patients detectable level HCV-RNA randomize Peginterferon a-2a mono-therapy treatment 72 week . - Group A : Peginterferon a-2a 90mg mono-therapy 72 week . - Group B : No CHC therapy 72 week All patient enter study require baseline liver biopsy ( within 18 month study entry ) . Patients enter 72-week randomized arm trial post-study liver biopsy upon completion trial . Study Population : 100 HIV infect adult chronic hepatitis C infection fail achieve sustain virologic response follow previous interferon therapy . Dosage Administration : Combo-therapy : Peginterferon a-2a 180mg subcutaneous route weekly plus Ribavirin : - 800 mg ( 400 mg bid ) body weight &lt; 65 kg - 1000 mg ( 400 mg a.m. 600 mg p.m. ) body weight &gt; 65 kg &lt; 85 kg - 1200 mg ( 600 mg bid ) body weight &gt; 85 kg Mono-therapy : Peginterferon a-2a 90mg 1mL solution administer subcutaneously weekly . Efficacy Evaluations : Laboratory analysis , liver biopsy , quality life assessment , change Peginterferona-2a Ribavirin dosage obtain . Safety Evaluations : - Assessment laboratory evaluation - vital sign - incidence severity adverse experience - dose adjustment - premature withdrawal safety reason - progression disease measure HCV viral load - AIDS define event</brief_summary>
	<brief_title>HRN 004- Peginterferon a-2a Plus Ribavirin Chronic Hepatitis C Infection HIV Infected Persons Who Have Failed Achieve Sustained Virologic Response Following Previous Interferon Therapy</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>To eligible trial , patient must documentation follow : 4.2.1 Written inform consent specific protocol obtain prior screen willingness participate comply study . 4.2.2 Male female patient &gt; 18 year age . 4.2.3 Detectable plasma HCVRNA RTPCR assay ( bDNA ) . 4.2.4 HCV genotype result must available screening ( historical determination genotype acceptable ) . 4.2.5 Evidence HIV infection ( reactive HIV antibody Western blot confirmation ) . 4.2.6 Chronic liver disease consistent chronic hepatitis C infection biopsy , judge qualified pathologist , obtain within past 18 month . For participant , liver biopsy report biopsy specimen ( H E slide Trichrome slide ) must make available review central pathologist . 4.2.7 Previous antiviral treatment alfa interferon monotherapy , interferon alfa plus ribavirin combination therapy administer least 12 week failure obtain sustained virologic response . 4.2.8 No therapy interferon interferon plus ribavirin specific antiHCV medication within 4 week screen . 4.2.9 Compensated liver disease follow laboratory parameter screen ( result within 1 month screen ) : Hemoglobin value ³ 11 gm/dL WBC ³ 3,000/mm3 Neutrophil count ³1,250/mm3 Platelets ³ 70,000/mm3 Prothrombin time £ 3 second prolonged compare control , equivalent INR ratio Bilirubin within 20 % upper limit normal ( unless nonhepatitis related factor Gilbert 's disease use indinivir explains indirect bilirubin rise ) . Albumin ³ 3.0 g/dL Serum creatinine £ 1.4 mg/dL Fasting blood sugar £ 115 mg/dL nondiabetic patient Hemoglobin A1C £ 8.5 % diabetic patient ( whether medication and/or diet control ) 4.2.10 Thyroid Stimulating Hormone ( TSH ) within normal limit thyroid disease clinical control ( within 3 month screen ) 4.2.11 Alphafetoprotein ( AFP ) value within normal limit obtain within prior year . For patient result upper limit normal &lt; 100 ng/mL follow require : Alphafetoprotein value &lt; 100 ng/mL obtain within 3 month prior entry AND Ultrasound obtain within 3 month prior entry negative evidence hepatocellular carcinoma . 4.2.12 CD4 T cell count HIV RNA level ( RTPCR ) within 4 week screening : CD4 &lt; 100 Eligible HIV RNA &lt; 25,000 RTPCR CD4 &gt; 100 Eligible HIV RNA level RTPCR 4.2.13 Stable antiretroviral regimen FDAapproved agent least 4 week prior baseline take antiretroviral agent within 4 week prior baseline . 4.2.14 Reconfirmation documentation sexually active female patient childbearing potential practicing adequate contraception ( intrauterine device , oral contraceptive , progesterone implant rod [ Norplant ] , medroxyprogesterone acetate [ DepoProvera ] , surgical sterilization , barrier method [ diaphragm + spermicide ] , monogamous relationship male partner vasectomy use condom + spermicide ) treatment period 6 month discontinuation therapy . Female patient must breast feed treatment period 6 month discontinuation therapy . A urine pregnancy test obtain entry prior initiation treatment must negative . 4.2.15 Reconfirmation documentation sexually active male patient practice acceptable method contraception ( vasectomy , use condom + spermicide , monogamous relationship female partner practice acceptable method contraception ) treatment period 6 month discontinuation therapy . 4.2.16 Anyone high risk coronary artery disease stress test perform prior entry . This would include , limited , patient age 55 history ischemia significant history hypertension , diabetes mellitus , obesity , smoke and/or strong family history coronary artery disease . Patients evidence ischemia rest stress EKG , history arrhythmia , angina myocardial infarction within 12 month must exclude . Patients meet follow criterion eligible trial : 4.3.1 Inability unwillingness provide write informed consent specific protocol unwillingness participate comply study . 4.3.2 Women ongoing pregnancy breast feeding . 4.3.3 Male partner woman pregnant . 4.3.4 Hypersensitivity interferon ribavirin . 4.3.5 Evidence advance liver disease history presence ascites , bleed varix , spontaneous encephalopathy . 4.3.6 Any cause chronic liver disease chronic hepatitis C. 4.3.7 Hemoglobinopathies ( e.g. , Thalassemia ) cause hemolytic anemia . 4.3.8 Any known preexisting medical condition could interfere patient ’ participation protocol include : CNS trauma active seizure disorder require medication ; poorly control diabetes mellitus ; serious pulmonary disease ; immunologicallymediated disease ; gout ; medical condition requiring , likely require course study , chronic systemic administration steroid . 4.3.9 Patients evidence ischemia stress test ( require patient risk history coronary artery disease , ECG evidence ischemia , arrhythmia , cardiac failure , coronary surgery , uncontrolled hypertension , angina myocardial infarction within 12 month . 4.3.10 Active acute HIVrelated opportunistic infection . 4.3.11 Evidence severe retinopathy ( e.g . CMV retinitis , macular degeneration ) 4.3.12 History major organ transplantation exist functional graft ( include Bone Marrow Transplants ) 4.3.13 History systemic antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) £6 month prior first dose study drug expectation treatment need time study . 4.3.14 Concomitant medication , rifampin/rifampicin , rifabutin , pyrazinamide , isoniazid , ganciclovir , thalidomide , oxymetholone ( Anadrolâ ) , immunomodulatory treatment ( include supraphysiologic dos steroid ) . 4.3.15 Evidence alcohol and/or drug abuse within one year entry . Patients methadone program exclude . 4.3.16 Inability abstain alcohol throughout entire course treatment followup . 4.3.17 History severe psychiatric disease , especially depression . Severe psychiatric disease define treatment antidepressant medication major tranquilizer therapeutic dos major depression psychosis , respectively , least 3 month previous time history follow : suicidal attempt , hospitalization psychiatric disease , period disability due psychiatric disease . 4.3.18 History evidence severe illness condition would make patient , opinion investigator , unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>